Latest Earnings Results: Q2 '26
Estimated EPS
-$0.54
Reported EPS
-$1.44
Surprise
-166.19%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
Definium Therapeutics reported a net loss of $158.986 million for the three months ended June 30, 2026, with cash, cash equivalents and investments totaling approximately $1.1 billion at period end.
Bullish Takeaway
Definium Therapeutics achieved positive Phase 3 efficacy results for its lead MDD candidate and maintains a robust cash balance of $1.1 billion, providing a long runway for continued clinical development.
Bearish Takeaway
Definium Therapeutics faces significant financial pressure from substantial net losses, rising non-cash warrant liabilities, and a lack of revenue, necessitating ongoing capital raises to fund its clinical development pipeline.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.53 | -- | -- | N/A |
Q2 '26 | -$0.54 | -$1.44 | -166.19% | MISSED |
Q1 '26 | -$0.49 | -$0.71 | -44.27% | MISSED |
Q4 '25 | -$0.48 | -$0.51 | -5.44% | MISSED |
Q3 '25 | -- | -$0.78 | -- | N/A |